Insulin, Neurogenetics and Memory in Alzheimer's Disease

Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic Approach

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00018382

Enrollment

Unknown

Registered

2001-07-05

Start date

1999-10-31

Completion date

2003-03-31

Last updated

2009-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Brief summary

This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.

Interventions

DRUGrosiglitazone

Study design

Allocation

RANDOMIZED

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

55 Years to 80 Years

Healthy volunteers

Inclusion criteria

Men and women with mild Alzheimer's Disease without serious medical or psychiatric comorbid conditions.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026